Skip to main content
. 2001 Oct 30;98(23):13306–13311. doi: 10.1073/pnas.231474098

Figure 5.

Figure 5

GFAP+ enteric glial cell populations in human IBD. (A–C) Immunohistochemistry for GFAP in control, involved CD and UC samples, respectively (×100). (D) Box plot demonstrating tissue GFAP levels (ng/mg protein) in clinical biopsies measured by Western blot and ELISA. Clinical groups have been nominated as histological normal controls (CONT; n = 33), noninvolved CD (CD-N; n = 39), involved CD (CD-I; n = 23), noninvolved UC (UC-N; n = 10), and involved UC (UC-I; n = 15). Ileal and colonic biopsies have been pooled because no significant differences were observed between the sites for the different groups. Significant differences (Mann–Whitney U test) from CONT are indicated as (a) included CONT vs. CD-N (P = 0.0005 and P < 0.0001 for Western blot and ELISA, respectively), and CONT vs. UC-I (P = 0.0045 and P = 0.0064 for Western blot and ELISA, respectively). b indicates a significant difference between CD-N and CD-I (P = 0.0058 and P = 0.0001 for Western blot and ELISA, respectively). c indicates a significant difference between UC-N and UC-I (P = 0.023 and P = 0.0009 for Western blot and ELISA, respectively). Significant differences also were recorded between CD-N and UC-N (P = 0.024 and P = 0.0009 for Western blot and ELISA, respectively) and CD-I and UC-I (P = 0.009 and P = 0.0176 for Western blot and ELISA, respectively).